Fig. 3

SHP-1 agonist shows anti-proliferation activity. A DLBCL cells treated with SC-43 at the indicated doses for 72 h were assessed by MTT assay. B U2932 and DB cells treated with SC-43, ibrutinib or ruxolitinib at the indicated doses for 72 h were assessed by MTT assay. C U2932 and DB cells treated with SC-43, ibrutinib or ruxolitinib at the indicated doses for 48 h were analyzed by flow cytometry. Data are representative of three independent experiments